March 2025

This month has seen the CEO attending several conferences including ERIG’s Big Molecules and Big Data part of their Research & Innovation 2025 program. May great talks and networking opportunities,

And The BMCS Mastering MedChem IX: 9th RSC-BMCS Symposium on Mastering Medicinal Chemistry at Burlington House, London,. The venue was ideal for the conference with excellent interactions between delegates, presenters, and vendors.

BOS Manchester 2024

The CEO of Awridian Ltd will be attending BOS Manchester 2024. The event is held at Manchester Central on 26th and 27th November .

Biotech Outsourcing Strategies Events bring together stakeholders in R&D outsourcing to share experience, build existing outsourcing partnerships and forge new buyer/supplier business relationships. BOS is an event where business gets done and where you can be confident of high quality interactions with potential business partners. You will receive a warm welcome from the Bio2Business team in the vibrant and buzzing City of Manchester!

https://www.bio2bevents.com/bosmanchester2024

BMCS Conformational Design in Drug Discovery 2024

The CEO of Awridian Ltd was at this RSC meeting on 7th March.

A synopsis From the RSC website:

Conformational Design has played a key role in the medicinal chemistry of small molecule clinical candidates over the last 20 years. A key learning from multiple projects supported by experimental free ligand NMR solution conformations and protein-ligand X-ray structures is that the bioactive conformation of potent ligands is highly populated in solution. Ligand rigidification has been particularly successful in the design of selective and potent protein-protein interaction inhibitors and is becoming an increasingly important approach for PROTACs, molecular glues and other new modalities. This new RSC-BMCS event aims at building a community that shares conformational design strategies, technologies, and successful case studies. It will complement other rational drug design events and promote more successful research into future medicines.

BOS Manchester 2023

Duncan the CEO of Awridian Ltd will be attending BOS2023 on 28th and 29th November, Manchester Central! He will be chairing a session entitled: OUTSOURCING CASE STUDIES ay 11.30 on the 29th. Look forward to seeing you there.

https://www.bio2bevents.com/bosmanchester2023

SMR RSC RECENT TRENDS IN MEDICINAL CHEMISTRY AND ENABLING TECHNOLOGIES

Duncan will be attending the SMR RSC RECENT TRENDS IN MEDICINAL CHEMISTRY AND ENABLING TECHNOLOGIES to be held Friends House, 173-177 Euston Road, London NW1 2BJ, on 8th Dec 2022.

This will be a combination of medicinal chemistry, chemistry-based drug discovery enabling technologies and chemical biology from academic, industry and not-for-profit groups.

The meeting will be primarily focused on talks from UK groups to reflect the breadth of work taking place across the UK to advance our understanding and prosecution of targets, technologies and lead series to underpin medicines research.

Hope to see you there!

ELRIG

The CEO of Awridian Ltd attended the ELRIG Conference and Trade show held at London’s ExCel centre in Oct 2022. There was a good range of presentation and exhibitors. The poster session was also a highlight.

SMR INNOVATIVE NEW PHARMA AND BIOTECH PARTNERSHIPS: HOW IS THE LANDSCAPE TRANSFORMING?

An overview from the SMR:

Currently neither traditional Pharma nor big tech companies have the full end-to-end capabilities to compete effectively in the future healthcare market alone, which has led to an evident and significant increase in their partnerships. These partnership aims to exploit the many new scientific breakthroughs, to empower consumers to take control of their own health, to increase development of personalised therapies, to speed up drug discovery and ultimately decrease the healthcare cost at the global level.

Despite the promise of many benefits for these partnerships, the industry must proceed with caution. The speed of technological innovation means that regulation and monitoring can struggle to keep pace. This could potentially jeopardise patients’ confidentiality, genetic privacy and even their health.

A panel of experts from industry, CROs, medical charities and VCs will share some of their experiences and lessons learned on how these institutions have developed strategies to deal with this evolving landscapes.

A very informative day.

33rd Medicinal Chemistry in Eastern England

The ‘Hatfield Chemistry’ meeting which returned on Thursday, 28th April 2022 at the Fielder Centre, Hatfield UK. It was great to be there, an excellent conference with excellent presentations, and importantly the chance for networking.